Introducing Agonist Redirected Checkpoint (ARC) Therapeutics for Cancer Immunotherapy and Inflammation.
Shattuck Labs is developing a breakthrough platform for immunotherapy, which harnesses the human immune system to improve survival for patients battling cancer and inflammatory disease. Shattuck has developed immunotherapy agents for patients with many cancer types, including melanoma, lung, and bladder. Shattuck’s proprietary technology represents the next evolutionary step in cancer therapy by endowing one molecule with multiple functions, building directly on the clinical success of Opdivo, Keytruda and Tecentriq, with applicability across the entire spectrum of human disease.
Shattuck Labs, based in Austin, Texas, is a privately-held biotechnology company founded in 2016 by Josiah Hornblower (CEO, Chairman, and Co-founder) and Taylor Schreiber, MD, PhD (Chief Scientific Officer, Co-founder).
Shattuck has attracted a world-class group of executives, directors and scientific advisors to lead development of the ARC platform and guide corporate strategy.
BOARD OF DIRECTORS
CEO, Chairman, and Co-founder
Taylor H. Schreiber, MD, PhD
Chief Scientific Officer, Co-founder
Neil Gibson, PhD
Chief Scientific Officer, Biologics, COI Pharma
David G. Lowe, PhD
Investor and Entrepreneur
G. Walter Loewenbaum
Chairman of the Board & Executive Committee, Luminex
Portfolio Manager, Lennox Capital Partners, LP
Lini Pandite, MD
Chief Medical Officer
Andrew R. Neill
Vice President of Corporate Development & Strategy
George Fromm, PhD
Vice President of Research & Development
SCIENTIFIC ADVISORY BOARD
Keith T. Flaherty, MD
Dana-Farber / Harvard Cancer Center
Charles G. Drake, MD, PhD
Columbia University Medical Center
Johann De Bono, MD, PhD
The Institute of Cancer Research
Dmitry Gabrilovich, MD, PhD
The Wistar Institute
Matthew Hellmann, MD
Memorial Sloan Kettering Cancer Center
Shattuck has attracted an outstanding base of early investors and partners as a result of its immunology and development expertise and the transformative potential of the ARC platform.